- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ipsos Healthcare Launches Syndicated MS Patient Community Panel
Ipsos Healthcare has announced the launch of its syndicated Multiple Sclerosis (MS) Patient Community Panel, part of the Ipsos Healthcare Global Patient Centre of Excellence. The MS Patient Community Panel comprises MS patients across the EU5 and US with a mix of treatment experiences. They will take part in a range of tasks throughout the year (both syndicated and proprietary), moderated by Ipsos Healthcare’s MS experts. This format will enable subscribers to explore key topics throughout the year, whilst also tapping into the community to answer business questions as they arise. Paul O’Meara, Head of Real World Evidence in Autoimmune Diseases at Ipsos Healthcare, commented: “As patients move from recipients to participants, there is an imperative for pharma to put patients at the heart of current and future business models. Designed with this objective in mind, the MS Community will enable our clients to identify unmet patient needs, optimise their patient communications, assess new ideas, and develop personalized medicine strategies for those living with MS.”
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.
